TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: AMD 3100 for Treatment of Myelokathexis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 years, WBC (white blood count) less than 3.0 x 10\^9 per Liter,~* Absolute neutrophil count less than 2.0 x 10\^9 per Liter,~* platelets greater than 100 x 10\^6 per Liter, creatinine less than 2.0/milligrams per/deciliter,~* Creatinine clearance \> 60 ml/min calculated,~* Aspartate Aminotransferase-GOT (SGOT), Alanin Aminotransferase-GPT (SGPT), bilirubin \< 2.5 upper limit of normal,~* Eastern Cooperative Oncology Group (ECOG) status 0 or 1,~* mutation identified and confirmed in CXCR4,~* on no granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage-colony stimulating factor (GM-CSF) within 3 weeks of the study drug~* patient signs consent, accepts contraception~Exclusion Criteria:~* greater than 18 years of age,~* sensitivity to plerixafor,~* pregnant,~* prisoner,~* decisionally impaired,~* judged unlikely to comply,~* illness that may interfere with interpretation of results,~* leukemia,~* malignancy,~* active infection requiring antibiotics within one week of study drug administration,~* history of cardiac conduction or electrocardiogram (EKG) abnormality,~* previous experimental therapy within one week.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMD3100 or plerixafor (Type: EXPERIMENTAL): SINGLE arm study with increasing doses of Plerixafor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Infant of either gender, aged 50 to 70 days inclusive~* Mother is negative for HBsAg~* Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg~* Written informed consent form signed by at least one parent or by another legal representative and an independent witness~* Parent/legal representative able to attend scheduled visits and to comply with the trial procedures during the entire duration of the trial.~Exclusion Criteria :~* Axillary temperature ≥37.1°C on the day of inclusion~* Current or planned enrolment in another clinical trial during the clinical trial period~* Known mother's history of Human Immunodeficiency Virus (HIV) infection~* Known immunodeficiency (congenital or acquired) or induced by immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy since birth, or systemic corticosteroids in the last 4 weeks (≥0.5 mg per kilogram and per day equivalent prednisolone and lasting more than 7 days)~* Receipt of blood-derived products since birth~* Acute symptoms or severe chronic illness (e.g. cardiac, renal insufficiency, diabetes, auto immune disorders, congenital defect) that may interfere with conduct or completion of trial~* Occurrence of seizures since birth~* Hypersensitivity to any of the vaccine components~* Coagulopathy contraindicating intramuscular injection~* History of (documented) clinical or serological/microbiological confirmed infection due to pertussis, tetanus, diphtheria, polio, Haemophilus influenzae type b (Hib) or hepatitis B (HB) diseases~* History of vaccination against pertussis, tetanus, diphtheria, polio, Hib or HB infections~* Vaccination within the last 4 weeks.

- Gender: ALL
- Minimum Age: 50 Days
- Maximum Age: 70 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): DTaP IPV HB-PRP\~T vaccine group
- 2 (Type: ACTIVE_COMPARATOR): PENTAXIM™ and ENGERIX B® vaccines group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Modifying Cervical Bishop Scoring System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Primigravida Singleton pregnancy with mature fetus at term indicated for termination of pregnancy.~2. Cephalic presentation.~3. Medical indications for termination of pregnancy e.g.: Pre-eclampsia, uncontrolled diabetes at term..e.t.c,~4. Post-term pregnancy.~5. Fetal indication: signs of fetal compromise e.g.: decreased biophysical profile, poor umbilical Doppler indices, diminished liquor.~6. premature rupture of membranes (PROM) not going into spontaneous labor within 24 hours since onset.~7. Intrauterine fetal death (IUFD).~Exclusion Criteria:~1. they had true labor pains or clear onset of labor as diagnosed by cervical changes.~2. Previous uterine surgery (scared uterus).~3. Cephalo-pelvic disproportion.~4. Mal-presentations~5. Severe oligo-hydramnios i.e.: amniotic fluid index Less than 5.~6. Twin pregnancy.~7. Fetal macrosomia. -Growth beyond a specific threshold (weight above 4000g) 8) Placenta previa.~9) Fetal bradycardia in case of living fetus.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 34 Years
- Healthy Volunteers: t

Study Arms:
- Labour Induction (Type: None): 80 primigravidas undergoing bishop score calculation, trans-vaginal ultrasound assessment of cervical length \&, Modified bishop score calculation, then induction of labour at our hospital.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects (male of female) ≥ 18 years of age able to give informed consent to the study.~* Subjects with non-myeloid malignancies~* Receiving chemotherapy as part of their cancer treatment with at least 4 weeks of treatment remaining.~* Screening visit central laboratory hemoglobin (Hgb) ≤11 g/dL, but ≥8 g/dL.~* Ferritin between 100 and 800 ng/mL and transferrin saturation (TSAT) =\<35%~* Subjects must have Eastern Coopertative Oncology Group (ECOG) performance status of 0-2.~* Life expectancy of at least 6 months.~* Demonstrate the ability to understand the requirements of the study, willingness to abide by study restrictions and to return for the required assessments.~Exclusion Criteria:~* Previous participation in a ferric carboxymaltose clinical trial.~* Known hypersensitivity reaction to any component of ferric carboxymaltose.~* Subjects with overt bleeding~* Any anemia treatment within 4 weeks before inclusion (oral iron, IV iron, transfusion, or erythropoiesis-stimulating agents).~* Subjects on erythropoiesis-stimulating agents.~* Requiring dialysis for the treatment of chronic kidney disease.~* Any non-viral infection.~* Known positive hepatitis with evidence of active disease.~* Received an investigational drug within 30 days of screening.~* Alcohol or drug abuse within the past 6 months.~* Hemochromatosis or other iron storage disorders.~* Any other laboratory abnormality, medical condition or psychiatric disorders which in the opinion of the Investigator would put the subject's disease management at risk or may result in the subject being unable to comply with study requirements.~* Pregnant or actively trying to become pregnant (Female subjects who are of childbearing age must have a negative pregnancy test at screening and be practicing an acceptable method of birth control during the study).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Injectafer (Type: EXPERIMENTAL): 2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.
- Normal Saline (Type: PLACEBO_COMPARATOR): Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GORE Embolic Protection With Reverse Flow

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Carotid stenosis requiring revascularization and indicating either symptomatic status, with carotid stenosis ≥ 50% OR asymptomatic status with carotid stenosis ≥ 80%~* Target lesion is located in one of the following:(a) internal carotid artery (ICA) (b) bifurcation (c) common carotid artery (CCA) proximal to the bifurcation~* At Anatomic risk for adverse events from CEA (e.g. restenosis after a prior CEA) OR at Co-morbid risk for adverse events from CEA (e.g., unstable angina with ECG changes)~Exclusion Criteria:~* Recent surgical procedure within 30 days before or after the stent procedure~* Uncontrolled sensitivity to contrast media~* Renal Insufficiency~* Recent evolving, acute stroke within 21 days of study evaluation~* Myocardial infarction within 72 hours prior to stent procedure~* History of a prior major ipsilateral stroke with residual neurological deficits likely to confound the neurological assessments (e.g., NIHSS)~* Neurological deficits not due to stroke likely to confound the neurological assessments (e.g., NIHSS)~Angiographic Exclusion Criteria:~* Isolated ipsilateral hemisphere leading to subject intolerance to reverse flow~* Total occlusion of the ipsilateral carotid artery~* Pre-existing stent in the ipsilateral carotid artery OR the contralateral carotid artery that extends into the aortic arch~* Presence of a filling defect, thrombus, occlusion or string sign in the target vessel~* Severe lesion calcification restricting stent deployment~* Carotid stenosis located distal to target stenosis that is more severe than target stenosis~* \> 50% stenosis of the CCA proximal to target vessel~* Known mobile plaque in the aortic arch

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GFRS Pivotal Subjects (Type: EXPERIMENTAL): All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* For MAIN period (GHLIQUID-1516):~* Born small for gestational age (SGA) with birth weight and birth length below the 10th percentile for gestational age, and additional either birth length below or equal to -2.0 standard deviation score (SDS) or birth weight below or equal to -2.0 SDS for gestational age~* Growth failure with height at -2.0 SDS or below for chronological age (CA)~* Normal growth hormone (GH) production, defined as peak GH level \> 10 ng/mL in one GH provocation test~* For EXTENSION period (GHLIQUID-1517):~* Subjects who completed the main period~* Chronological age (CA) for boys at least 4 years, but maximum 11 years~* Chronological age (CA) for girls at least 4 years, but maximum 10 years~Exclusion Criteria:~* Subjects with diabetes mellitus~* Subjects suffering from malignancy~* Several medical conditions

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- 0.033 mg / NN-220 (Type: EXPERIMENTAL): In the 156-week main period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
- 0.067 mg / NN-220 (Type: EXPERIMENTAL): In the 156-week main period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
- No treatment (Type: NO_INTERVENTION): No somatropin (NN-220) treatment was given in the 52-week main period. Subjects was re-randomised to recive two dosing regimens (0.033 mg/kg/day or 0.067 mg/kg/day) in the 208-week extension period
- No treatment --> 0.033 mg (Type: EXPERIMENTAL): In the 208-week extension period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
- No treatment --> 0.067 mg (Type: EXPERIMENTAL): In the 208-week extension period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cohort Event Monitoring Study of Pyramax®

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Uncomplicated malaria (Plasmodia of any species) diagnosed as per national policies and in line with WHO recommendations:~  * Fever or history of fever in the previous 24 h and/or the presence of anaemia, for which pallor of the palms appears to be the most reliable sign in young children.~ * Confirmation of malaria by a parasitological diagnosis (RDT or Microscopy (thick blood smear). analysis).~* Weight ≥5 kg - \< 20 kg (granules); ≥20 kg (tablets).~* Ability to take an oral medication.~* Ability and willingness to participate based on signed informed consent (a parent or a guardian has to sign for children below 18 years old) and on signed assent form for minors that could be required per national regulations in each participating country.~* The patient has to comply with all scheduled follow-up visits.~Exclusion Criteria:~* Patients with clinical signs or symptoms of hepatic injury (such as nausea, abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, Child-Pugh stage 3 or 4).~* Known allergy to artemisinin and/or to pyronaridine.~* Known pregnancy.~* Lactating women should be excluded if other anti-malarial treatments are available.~* Complicated malaria as per WHO definition (Annex 2)~* Patients that the investigator considers would be at particular risk if receiving an anti-malarial or if participating in the study.~* Patients having been treated with Pyramax in the previous 28 days.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pyramax (Type: EXPERIMENTAL): Pyronaridine artesunate tablets (180/60mg) and granules (60/20mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Squamous or Non-Squamous, non-small cell lung cancer (NSCLC), Stage IIIb/IV (histologically or cytologically confirmed), EGFRm/T790M, who received osimertinib treatment within the Spanish special use medication program of Osimertinib (SUMP).~* Alive patients must have signed, dated and IRB/EC-approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.~Exclusion Criteria:~* Alive patients who do not want to sign and date an IRB/IEC-approved written informed consent form.~* Patients who were accepted in the SUMP, but did not receive treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interscalene Brachial Plexus Block Combined With Suprascapular Nerve Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. definite rotator cuff tear on preoperative MRI, which needed repair;~2. acceptance of arthroscopic surgery including rotator cuff repair;~3. \> 20 years old; and~4. acceptance of routine regional blocks and patient-controlled analgesia.~Exclusion Criteria:~1. did not want arthroscopic rotator cuff repair;~2. stopped PCA before 48 h postoperatively due to side effects;~3. history of shoulder operation or fracture;~4. concomitant neurological disorder around the shoulder;~5. conversion to open surgery from the arthroscopy; and~6. contraindication to the routine regional blocks in this study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ISB with SSNB (Type: EXPERIMENTAL): During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL ropivacaine.
- ISB alone (Type: PLACEBO_COMPARATOR): During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Biology of Resilience

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* age 22-65, BMI \< 30, healthy, English-speaking, 9th grade reading level.~Exclusion Criteria:~* any known medical condition (including mental disorders) or on any type of medication~* high levels of social anxiety~* smokers~* high rates of alcohol or drug use~* pregnant or suspected pregnant~* breastfeeding~* blood pressures \> 140/90 mm Hg~* subject does not have a close friend available to participate in the study with him/her

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Oxytocin (Type: EXPERIMENTAL): One primary experimental manipulation is the receipt of intranasal oxytocin vs placebo spray prior to participation in a psychosocial stress protocol
- Placebo (Type: PLACEBO_COMPARATOR): The comparison condition for receipt of oxytocin is receipt of a saline intranasal spray
- Social Support (Type: EXPERIMENTAL): Participants bring a friend to the laboratory who sits with them while they engage in the stress protocol tasks
- No Social Support (Type: PLACEBO_COMPARATOR): Individuals in this condition do not have a friend present while they are engaging in the laboratory protocol.
- Female Gender (Type: OTHER): Effects of oxytocin and social support are examined among women versus men
- Male Gender (Type: OTHER): Consider effects of oxytocin and social support in men versus women

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete